Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclic Adenosine Monophosphate SCHEMBL18716064 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL15893189 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL18934079 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL22434642 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829653 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829820 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829591 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829670 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829673 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL20912149 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024103125-A1 | METHOD OF MODIFYING CELLS | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024092321-A1 | METHODS OF ENHANCING ENDOTHELIAL BARRIER INTEGRITY | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024064701-A2 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20230293530-A1 | AGENTS FOR SENSITIZING SOLID TUMORS TO TREATMENT | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-09-21 | — | — | US | disclosed |
| US-11753455-B2 | Compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2023-09-12 | — | — | US | disclosed |
| US-20230203121-A1 | Incretin Analogs and Uses Thereof | ELI LILLY AND COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-11542313-B2 | Incretin analogs and uses thereof | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| CN-112312922-A | Novel compounds for the treatment of obesity | 诺和诺德股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | disclosed |
| EP-0705433-A4 | COMPOSITIONS AND METHODS FOR ANTI-ADDICTIVE NARCOTIC ANALGESIS ACIVITY SCREENING AND TREATMENTS | UNIV CALIFORNIA (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1124829-A1 | TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026218-A1 | TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-05-11 | — | — | WO | disclosed |
| CN-1248295-A | Species, genus specific and universal probes and primers for pathogen and related antibiotic resistance gene detection for diagnosis | INFECTIO DIAGNOSTIC INC (CA) | 2000-03-22 | — | — | CN | disclosed |
| EP-0943009-A2 | SPECIES-SPECIFIC, GENUS-SPECIFIC AND UNIVERSAL DNA PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR DIAGNOSIS IN MICROBIOLOGY LABORATORIES | Infectio Diagnostic (I.D.I.) INC. (CA) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998043992-A1 | CYCLIC ADENOSINE DIPHOSPHATE RIBOSE ANALOGUES | ISIS INNOVATION LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998020157-A2 | SPECIES-SPECIFIC, GENUS-SPECIFIC AND UNIVERSAL DNA PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR DIAGNOSIS IN MICROBIOLOGY LABORATORIES | INFECTIO DIAGNOSTIC (I.D.I.) INC. (CA) | 1998-05-14 | — | — | WO | disclosed |
| EP-0705433-A1 | COMPOSITIONS AND METHODS FOR ANTI-ADDICTIVE NARCOTIC ANALGESIS ACIVITY SCREENING AND TREATMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000848-A1 | COMPOSITIONS AND METHODS FOR ANTI-ADDICTIVE NARCOTIC ANALGESIS ACIVITY SCREENING AND TREATMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-01-05 | — | — | WO | disclosed |
| US-4950680-A | SYNERGISTIC ADMIXTURE OF A 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER, AND A PROSTACYCLIN | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339649-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | STING1 626/4885LMNA 2624/4885RAPGEF3 838/4885 |
| US-11753455-B2 | Compounds for treatment of obesity | GLP1R, TFRC, GIPR | STING1 3871/4885LMNA 3960/4885RAPGEF3 1305/4885 |
| US-11542313-B2 | Incretin analogs and uses thereof | GLP1R, GIPR, GCGR | STING1 3321/4885LMNA 2597/4885RAPGEF3 1052/4885 |
| US-20230203121-A1 | Incretin Analogs and Uses Thereof | GLP1R, GIPR, GCGR | STING1 3321/4885LMNA 2597/4885RAPGEF3 1052/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | STING1 824/4885LMNA 3399/4885RAPGEF3 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.